Pharmac is seeking public consultation on a proposal to fully fund oestradiol gel, an alternative to hormone replacement therapy (HRT) patches, without restrictions as supply issues persist.
Oestradiol was used by around 86,000 people in 2023/24 for the treatment of a range of conditions including menopause, osteoporosis, and gender affirming health care. It is most often used as a patch placed on the skin, but it can also be used as a gel or tablet.
Earlier this year, Pharmac asked pharmaceutical suppliers about the potential of securing oestradiol gel as an option for Kiwis following global challenges to supply crucial hormone replacement therapy patches.
Over the past three years demand for hormone replacement therapy (HRT) oestradiol patches has more than tripled, and prompted Pharmac to look at procuring funding for oestradiol gel in New Zealand.
In a statement today, Pharmac said it has now open consultation on its proposal to fully fund oestradiol gel (branded Estrogel) without restrictions, meaning it would be available for anyone who is prescribed it.
Pharmac director of equity and engagement Nicola Ngawati said that more than 18,000 people would benefit in the first year, if funding was approved.
“Funding a gel would be a great addition to the treatment options already available and would help alleviate the supply shortages that are causing stress and frustration for a number of people,” said Ngawati.
Menopause doctor Linda Dear said funding for alternatives such as gels would ease the supply situation.
“I’m so happy that New Zealanders could soon have the option of a fully funded oestradiol gel. The global supply issues with oestradiol patches have caused huge problems for people who use Hormone Replacement Therapy (HRT).
“Having the gel as an alternative will mean fewer people will struggle to obtain this often life-changing therapy,” she said.
Following public consultation, a funding proposal will be taken to Pharmac’s Board, or a delegate, for a decision.
Consultation closes at 5pm on August 15 and if approved, oestradiol gel is expected be available nationwide from November 1, 2024.